Literature DB >> 18320716

Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration.

Ewa Bałkowiec-Iskra1, Iwona Kurkowska-Jastrzebska, Ilona Joniec, Agnieszka Ciesielska, Anna Członkowska, Andrzej Członkowski.   

Abstract

Many data suggest involvement of inflammation in neurodegeneration. However, the exact mechanisms of this cooperation are poorly understood. We have previously shown that induction of inflammatory reaction, both before and after injury of the striatum, affects regeneration of dopaminergic neurons. In the present research we studied the role of inflammatory reaction in non-injured striatum. We used myelin oligodendrocyte glycoprotein (MOG) 35-55 in complete Freund's adjuvant (CFA) to elicit experimental autoimmune encephalomyelitis (EAE) mice model. As determined by HPLC, striatal dopamine (DA) and serotonin levels in mice treated with either MOG 35-55 in CFA or CFA alone were significantly higher compared to vehicle-treated controls on 13th day after induction. The ratio of homovanilic acid/dopamine (HVA/DA) and 3, 4 dihydroxyphenylacetic acid/dopamine (DOPAC/DA) were significantly lower in the MOG and CFA groups on 13th day, indicating decreased DA metabolism. Noradrenaline (NA) concentration did not differ between groups. Moreover, the striatal mRNA IL-1beta and TNF-alpha levels were elevated during induction phase of EAE in both groups, as determined by RT-PCR. Our data indicate regulatory connection between dopaminergic and immune systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18320716

Source DB:  PubMed          Journal:  Acta Neurobiol Exp (Wars)        ISSN: 0065-1400            Impact factor:   1.579


  8 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Dopamine, T cells and multiple sclerosis (MS).

Authors:  Mia Levite; Franca Marino; Marco Cosentino
Journal:  J Neural Transm (Vienna)       Date:  2017-03-10       Impact factor: 3.575

Review 3.  Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia.

Authors:  Nagahide Takahashi; Takeshi Sakurai; Kenneth L Davis; Joseph D Buxbaum
Journal:  Prog Neurobiol       Date:  2010-10-13       Impact factor: 11.685

Review 4.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

Review 5.  The dopaminergic system in autoimmune diseases.

Authors:  Rodrigo Pacheco; Francisco Contreras; Moncef Zouali
Journal:  Front Immunol       Date:  2014-03-21       Impact factor: 7.561

6.  Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.

Authors:  Carolina Prado; Francisco Osorio-Barrios; Paulina Falcón; Alexandra Espinoza; Juan José Saez; María Isabel Yuseff; Rodrigo Pacheco
Journal:  J Neuroinflammation       Date:  2021-12-17       Impact factor: 8.322

7.  Dopaminergic Stimulation of Myeloid Antigen-Presenting Cells Attenuates Signal Transducer and Activator of Transcription 3-Activation Favouring the Development of Experimental Autoimmune Encephalomyelitis.

Authors:  Carolina Prado; Michela Gaiazzi; Hugo González; Valentina Ugalde; Alicia Figueroa; Francisco J Osorio-Barrios; Ernesto López; Alvaro Lladser; Emanuela Rasini; Franca Marino; Mauro Zaffaroni; Marco Cosentino; Rodrigo Pacheco
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

8.  Dopamine Receptor D5 Signaling Plays a Dual Role in Experimental Autoimmune Encephalomyelitis Potentiating Th17-Mediated Immunity and Favoring Suppressive Activity of Regulatory T-Cells.

Authors:  Francisco Osorio-Barrios; Carolina Prado; Francisco Contreras; Rodrigo Pacheco
Journal:  Front Cell Neurosci       Date:  2018-07-10       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.